rns,,,14 Jan 2021 09:19
Further to the Company's announcement on 5 November 2020, Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, provides the following update in relation to the Memorandum of Understanding ("MOU"), signed in November 2020, for the supply and distribution of 30 million doses of the Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222 ("the Vaccine"), in Bangladesh, the status of regulatory approvals required and the Company's plans to purchase and distribute the Vaccine to the private healthcare market in Bangladesh.